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Abstract
Background: Analysis of chromosomal rearrangements within primary tumors has been influential in the identification of
novel oncogenes. Identification of the ‘‘driver’’ gene(s) within cancer-derived amplicons is, however, hampered by the fact
that most amplicons contain many gene products. Amplification of 1q21–1q23 is strongly associated with liposarcomas and
microarray-based comparative genomic hybridization narrowed down the likely candidate oncogenes to two: the activating
transcription factor 6 (atf6) and the dual specificity phosphatase 12 (dusp12). While atf6 is an established transcriptional
regulator of the unfolded protein response, the potential role of dusp12 in cancer remains uncharacterized.
Methodology/Principal Findings: To evaluate the oncogenic potential of dusp12, we established stable cell lines that
ectopically over-express dusp12 in isolation and determined whether this cell line acquired properties frequently associated
with transformed cells. Here, we demonstrate that cells over-expressing dusp12 display increased cell motility and resistance
to apoptosis. Additionally, over-expression of dusp12 promoted increased expression of the c-met proto-oncogene and the
collagen and laminin receptor intergrin alpha 1 (itga1) which is implicated in metastasis.
Significance: Collectively, these results suggest that dusp12 is oncologically relevant and exposes a potential association
between dusp12 and established oncogenes that could be therapeutically targeted.
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Introduction
Evaluation of the chromosomal region 1q21–1q23, frequently
amplified in primary liposarcomas, by fluorescence in situ hybrid-
ization and comparative genomic hybridization reduced the list of
candidate oncogenes contained by this amplicon to two genes: the
activating transcription factor 6 (atf6)a n dt h ed u a ls p e c i f i c i t y
phosphatase 12 (dusp12) [1]. ATF6 is a transcription factor involved
in the unfolded protein response (UPR) which responds to
endoplasmic reticulum (ER) stress [2]. While the UPR is indicated
to be involved in tumorigenesis [2], the role, if any, of DUSP12 in
tumorigenesis is not known. Interestingly, in four out of five
liposarcomas examined, dusp12 was expressed significantly higher
than atf6, suggesting that dusp12 may be the more relevant target of
the1q21–1q23chromosomalamplification[1].Inaddition,dusp12is
over-expressed in retinoblastomas, intracranial ependymomas, and
the most common childhood malignant tumor, neuroblastoma [3–
5]. As over-expression of dusp12 is observed in multiple cancer types,
it suggests that dusp12 may play an important role in cancer biology.
The dual specificity phosphatases (DUSPs) are members of the
protein tyrosine phosphatase (PTP) family that dephosphorylate
serine, threonine, and tyrosine residues [6] and are important
regulators of multiple signaling pathways that modulate cell
processes such as proliferation, apoptosis, and migration [7].
Misregulation of DUSPs, and hence the pathways they regulate,
play a major role in the development of many diseases, including
cancer and diabetes [8,9]. Members of the DUSP family can be
subdivided into subgroups based on the presence of specific
domains and sequence similarity. One poorly characterized
subgroup, the atypical DUSPs, do not fit into any better
characterized subgroups and often do not regulate known targets
of DUSPs such as mitogen activated protein kinases (MAPKs) [7].
DUSP12 is an atypical DUSP whose function in human cells is
poorly understood [7]. DUSP12 was identified as a potential pro-
survival phosphatase in an siRNA screen [10]. The identification of
DUSP12 as a pro-survival phosphatase has been supported by
experiments where transient over-expression of DUSP12 in HeLa
cells protects from apoptosis in response to a variety of apoptotic
stimuli [11]. Although DUSP12’s function is poorly characterized in
humans, DUSP12 is evolutionarily conserved, and DUSP12
homologs exist in yeast (GeneID: 854844), flies (GeneID: 32963),
fish (GeneID: 573998), nematodes (GeneID: 177903), and mice
(GeneID: 80915). Of these organisms, the function of DUSP12 has
been best characterized in the budding yeast, Sacchramyces cerevisiae,
where the gene is designated yvh1 [12]. Human DUSP12 and
Yvh1pshare 44% amino acid identity within their catalytic domain,
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domain (59% identity) of unknown function that is only found in
DUSP12 homologs. In S. cerevisiae, Yvh1p regulates cell growth and
morphogenesis [13]. Surprisingly, these abilities do not map to the
phosphatase domain, but to the C-terminal rich domain, as
catalytically inactive variants or variants that lack the entire N-
terminal phosphatase domain suppress the phenotypes of yvh1D
strains, suggesting a phosphatase independent role for Yvh1p
function [13,14]. Importantly, ectopic expression of wild-type or
catalytically inactive variants of the human dusp12 gene in yeast also
suppress the phenotypes of yvh1D strains, suggesting that the
function(s) of DUSP12 and Yvh1p are evolutionarily conserved
[14]. Recent work in yeast has also demonstrated that Yvh1p
participates in 60S ribosome maturation in a phosphatase-indepen-
dent manner [15,16]. Although, it is clear that the human DUSP12
can functionally complement multiple phenotypes associated with
yvh1 deletion in a phosphatase-independent manner [14], whether
DUSP12 functions similarly in human cells is currently unknown.
In this study, we have established for the first time, a stable cell
line that selectively over-expresses dusp12 in isolation and find that
this cell line demonstrates increased cell motility, increased
resistance to apoptotic stimuli, and has an increase in the
transcript levels of two genes previously implicated in carcinogen-
esis, the proto-oncogene c-met and the collagen and laminin
receptor itga1.
Results
Establishment of HEK293 cells stably over-expressing
gfp-dusp12 in isolation
To evaluate the consequences of specific dusp12 over-expression,
we established human embryonic kidney cells (HEK293), an
immortalized, but non-tumorgenic cell line [17] that stably over-
expresses GFP or GFP-DUSP12 (Figure 1). Microscopic exami-
nation of the GFP-DUSP12 cell line revealed that they are
morphologically similar in overall appearance to the GFP control
cell line with the exception of more cortical actin present in the
GFP-DUSP12 cell line (Figure 1A). In addition, there is no
significant difference between the two cell lines under starvation
conditions (Figure 1A). The GFP-DUSP12 cell line has close to a
60 fold increase in dusp12 expression compared to the control GFP
cell line that only expresses endogenous dusp12 as measured by
qRT-PCR (Figure 1B). Expression of the full-length GFP-DUSP12
fusion protein was confirmed by immunoblotting (Figure 1C). All
the data shown were generated with the use of one individual
clone designated F78; however we observed similar results in other
individual clones as well as in transient expression assays,
suggesting that the phenotypes observed are not due to disruption
of an unknown gene caused by the insertions of gfp-dusp12 into the
genome (data not shown).
Over-expression of dusp12 does not promote
proliferation or anchorage independent growth
As dusp12 has been described as a potential driver for the 1q21–
1q23 amplicon [1] and many oncogenes promote proliferation
[18], we addressed whether over-expression of dusp12 affected
proliferation. Equivalent numbers of GFP and GFP-DUSP12 cells
were seeded at day 0 and proliferation was assessed as a function of
time by measurement of cellular ATP levels. We found no
significant difference between cells over-expressing gfp-dusp12
compared to the cell line over-expressing gfp alone (Figure 2A).
As anchorage independent growth is another common property of
some transformed cell lines, we asked whether dusp12 over-
expression allowed for growth in soft agar. Although we noted a
slight increase in the number of colonies in the GFP-DUSP12 cell
line after 21 days, there was no significant difference between the
GFP-DUSP12 and GFP control cell line in either colony number
or size (Figure 2B).
Over-expression of dusp12 promotes cell motility
Since dusp12 over-expression is strongly associated with invasive
liposarcomas [1], we tested the hypothesis that DUSP12 over-
expression affects cell motility using a scratch wound assay. We
observed that the GFP-DUSP12 cells were able to close the wound
faster than the control cell line (Figure 3A). In order to better
quantify the difference in cell motility, we conducted a
transmigration assay using fetal bovine serum as the chemoat-
tractant. The GFP-DUSP12 cell line had a statistically significant
1.2 fold increase in cell motility compared to the GFP control cell
line (Figure 3B). Collectively, these results suggest that the selective
over-expression of dusp12 leads to increased cell motility.
Over-expression of dusp12 protects cells from apoptosis
Another common property of oncogene expression is the
resistance to programmed cell death. In order to determine
whether ectopic over-expression of dusp12 affected apoptosis, we
treated the GFP and GFP-DUSP12 cell lines with staurosporine
(STS) a broad specificity kinase inhibitor that has been widely used
to induce apoptosis in a variety of different cell types. Apoptosis
was quantified by means of a luminescent Caspase 3/7 assay and
by immunoblotting to detect cleaved PARP, a validated apoptosis
marker [19]. Treatment of the control cell line with STS led to a
significant increase in both Caspase 3/7 activity (Figure 4A,
leftmost panel) and PARP cleavage (Figure 4A, right panel). The
GFP-DUSP12 cells demonstrated both a reduced level of Caspase
3/7 activity and PARP cleavage after STS treatment. To ensure
that these results were not specific to STS-induced apoptosis, we
repeated these experiments using thapsigargin (TG), which
induces the unfolded protein response (UPR) by perturbation of
Ca
2+ levels [20]. Similar to STS, over-expression of gfp-dusp12 led
to a decrease in both Caspase3/7 activity and PARP cleavage
induced by TG (Figure 4B). Collectively these results indicate that
cells ectopically over-expressing dusp12 have an increased
resistance to apoptosis induced by different stimuli.
Over-expression of dusp12 up-regulates the proto-
oncogene c-met and the metastasis factor itga1
To further characterize the consequences of ectopic dusp12
expression, we used a Cancer Gene PCR array to compare the
transcript levels of 84 genes previously implicated in transforma-
tion or tumorigenesis on RNA samples extracted from the GFP
and GFP-DUSP12 cell lines. Candidate genes were identified as
those demonstrating greater than a two-fold expression difference
in the GFP-DUSP12 cell line compared to the GFP control cell
line. This approach initially identified five candidate genes that
were up-regulated by DUSP12: bcl-2, cflar, itga1, vegfa, and c-met.
To confirm the initial PCR array results, qRT-primers for these
genes were obtained and additional qRT-PCR analysis was
performed using independent RNA samples extracted from the
GFP and GFP-DUSP12 cell lines. This experiment confirmed that
intergrin alpha 1 (itga1) and the hepatocyte growth factor receptor
tyrosine kinase (c-met) transcripts were significantly up-regulated in
cells over-expressing dusp12 (Figure 5A). The increased expression
was also reflected at the protein level since western blots using
c-MET and ITGA1 specific antibodies demonstrated increased
amounts of these proteins in GFP-DUSP12 cells compared to the
GFP control cell line (Figure 5B), suggesting that the increased
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PLoS ONE | www.plosone.org 2 April 2011 | Volume 6 | Issue 4 | e18677Figure 1. Establishment of HEK293 cells stably over-expressing either gfp or gfp-dusp12 in isolation. A. Confocal images of HEK293 cells
stably expressing GFP or GFP-DUSP12. Cells were seeded on a fibronectin coated chamber slide. After attachment, cells were washed with PBS and
complete or serum free media was added to the cells. After 18 hours, cells were fixed and stained with rhodamine-phalloidin and DAPI and viewed
using confocal microscopy (magnification6100). B. Quantitative Real Time PCR was used to compare the expression level of dusp12 in GFP-DUSP12
and GFP stable lines. dusp12 specific primers were used and normalized to the average of the genes b2m, actb, and gapd genes. The fold change was
calculated using the DDCt method. The mean of three independent experiments is graphed with error bars representing SEM. C. Immunoblot
detecting GFP or GFP-DUSP12 in HEK293 stable lines. A single clone of GFP or GFP-DUSP12 cells was lysed in RIPA buffer. Equivalent amounts of
lysates were fractionated by SDS-PAGE and GFP and GFP-DUSP12 were detected with a GFP specific antibody. The blot was also probed with a total
ERK 1/2 specific antibody as a loading control. Numbers to the right of the blot indicate molecular weight.
doi:10.1371/journal.pone.0018677.g001
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consequences.
Discussion
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to investigate whether over-expression of dusp12 promotes oncogenic
properties in a cell culture model. To our knowledge, this is the first
time in which a stable cell line over-expressing dusp12 in isolation has
been described. This study demonstrates that over-expression of
dusp12, may promote cancer development and progression by
increasing migration and cell survival. Results obtained from the
GFP-DUSP12 cell line can be replicated in transient assays where a
Flag tagged DUSP12 is expressed in HEK293 cells (Figure S1),
showing that GFP is not altering DUSP12 function and that the
phenotypes observed are not due to clonal variation.
The up-regulation of c-met and itga1 in cells over-expressing
dusp12 further indicates that dusp12 may function as a novel
oncogene, since ITGA1 is known to promote proliferation,
invasion, angiogenesis, and metastasis [21–25], while c-MET
can affect proliferation, survival, and migration [26–28]. The
ability of DUSP12 to up-regulate c-MET and ITGA1 may explain
the increased cell motility observed in the GFP-DUSP12 cell line
since both of these proteins are known to increase cell migration
[25,28]. As DUSP12 is known to be over-expressed in invasive
sarcomas [29,30], and we have demonstrated that selective up-
regulation of DUSP12 leads to increased c-met expression, it would
be interesting to examine whether primary sarcomas containing
the 1q21–1q23 amplicon also demonstrate increased expression of
the c-met proto- oncogene.
In addition to regulating the expression of two genes previously
implicated in various aspects of tumorgenesis, we found that
Figure 2. Selective over-expression of dusp12 does not affect proliferation or anchorage independent growth. A. Proliferation assay
was performed by measuring viable cells over time with the Promega Cell Titer-Glo assay. Time zero was the measurement of GFP or GFP-DUSP12
cells immediately after seeding the wells. The means of three independent experiments are graphed with the error bars representing SEM. B. GFP or
GFP-DUSP12 cells were suspended in soft agar for three weeks. Colony number and size were measured using ImageJ in five fields of vision. The
mean of three independent experiments are shown and the error bars represent SEM.
doi:10.1371/journal.pone.0018677.g002
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dusp12 was identified as a pro-survival gene in an siRNA screen
using HeLa cells [10]. This was supported by other experiments
where transient over-expression of dusp12 protected HeLa cells
from apoptosis induced by a variety of stimuli [11]. Our results
with the immortal, but non-tumorigenic, HEK293 cell line suggest
that DUSP12 over-expression can promote apoptosis resistance is
the third instance of dusp12 being described as a pro-survival gene,
and suggests that DUSP12 can protect from apoptosis in a variety
of cellular contexts. The ability of DUSP12 to promote apoptosis
resistance may be due to the up-regulation of c-MET which has
been described to promote cell survival [27]. However, we were
unable to detect c-MET activation by immunoblotting with an
antibody specific to c-MET phosphorylated at Tyr 1234/1235
(data not shown), suggesting that DUSP12 may protect from
apoptosis in a manner independent of c-MET activation.
Investigations into mechanisms by which DUSP12 can protect
from apoptosis are ongoing.
c-met is over-expressed in many different neoplastic diseases
[31]. Studies have found that over-expression of c-met imbues cells
with properties of cellular transformation, however, properties
such as anchorage independent growth require the c-MET ligand,
hepatocyte growth factor (HGF), supplied either in an autocrine or
paracrine manner [26,27,29,30,32–34]. Our inability to observe c-
MET activation, growth in soft agar, or increases in proliferation
in the GFP-DUSP12 cells may be due in part to the low expression
of HGF by HEK293 cells [33]. Although growth in soft agar is
often used as a metric for cellular transformation, not all
oncogenes are capable of promoting anchorage-independent
growth. Notably, over-expression of the bcl-2 oncogene in normal
rat epithelial cells (WBF443) and JB6 mouse epidermal cells, does
not affect growth rate nor does it allow for anchorage independent
growth [35,36]. We speculate that in the correct cellular context
and microenvironment DUSP12’s ability to up-regulate c-MET
could result in cellular transformation. For reasons that are not
well understood despite repeated efforts we were able to recover
Figure 3. Over-expression of dusp12 promotes cell motility. A. A scratch wound assay was performed on confluent GFP and GFP-DUSP12 cells
and the wound closure was monitored over time. Above is a representative experiment of three independent experiments. B. A transmigration assay
using 0.8 mm HTS Fluoroblok transmigration chambers was performed with fetal bovine serum as the chemoattractant. Cells were pre-labeled with
calcein AM and added to the wells in serum free media. After 22 hours the total number of live cells was measured and the percent of total cells that
migrated to the lower chamber are graphed. The means of three independent experiments are graphed with the error bars representing SEM.
Significance of a P value,0.05.
doi:10.1371/journal.pone.0018677.g003
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PLoS ONE | www.plosone.org 5 April 2011 | Volume 6 | Issue 4 | e18677Figure 4. Over-expression of dusp12 protects cells from apoptosis. A. Left: GFP or GFP-DUSP12 cells were treated with DMSO or 5 mM
staurosporine (STS) overnight and the Promega Caspase 3/7 Glo assay was used to measure apoptosis. Means of three independent experiments are
graphed with error bars representing SEM. Significance of a P value,0.05. Right: Immunoblot detecting cleaved PARP in lysates of GFP and GFP-
DUSP12 cells treated overnight with 5 mM STS. Lysates were collected with RIPA buffer and equalized by total protein using a BCA assay. A
representative blot from three independent experiments is shown. B. Left: GFP or GFP-DUSP12 cells were treated with DMSO or 200 nM
thapsigargin (TG) for 48 hours and the Promega Caspase 3/7 Glo assay was used to measure Caspase 3/7 activation as an indication of apoptosis.
Means of three independent experiments are graphed with error bars representing SEM. Significance of a P value,0.05. Right: Immunoblot
detecting cleaved PARP in lysates of GFP and GFP-DUSP 12 cells treated with 200 nM TG for 48 hours. Lysates were collected with RIPA buffer and
equalized by total protein using a BCA assay. Results depicted are representative of at least three independent experiments.
doi:10.1371/journal.pone.0018677.g004
Figure 5. Over-expression of dusp12 up-regulates the proto-oncogene c-MET and the metastasis factor ITGA1. A. The expression levels
of five proto-oncogenes in GFP-DUSP12 cells were compared to the expression levels in GFP cells and normalized to the average of the housekeeping
genes b2m, actb, and gapd. The fold change was calculated using the DDCt method. The mean of three independent experiments is graphed with
error bars representing SEM. * indicates P value,0.05. B. Immunoblot of GFP and GFP-DUSP12 cells probed with c-MET, ITGA1, and ERK 1/2 specific
antibodies. Lysates were collected in RIPA buffer and equalized by total protein as measured by a BCA assay. The blot shown is a representative blot
of three independent experiments.
doi:10.1371/journal.pone.0018677.g005
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fusion, from a human fibrosarcoma (HT1080), cervical adenocar-
cinoma (HELA), breast adenocarcinoma (MCF-7) or a mouse
fibroblast (NIH3T3) cell line (data not shown).
At this time, investigations are ongoing that are examining how
DUSP12 can cause the phenotypes described here. Of interest is
whether the phosphatase or the unique cysteine rich domain of
DUSP12 is required for the up-regulation of genes and increases in
survival and cell motility. Previous work in HeLa cells suggests that
the pro-survival function of DUSP12 is dependent on phosphatase
activity [11]. However, Yvh1p affects yeast growth [13,14] and
promotes 60S ribosome maturation [15,16] in a phosphatase
independent manner. Both protein translation and ribosome
biogenesis are coordinated with cell proliferation, and interfering
with these processes can retard cell growth and animal
development [37]. A role for ribosome biogenesis in cancer
progression comes from the recent observation that c-MYC
localizes to nucleoli where it functions as a regulator of ribosome
biogenesis [38]. Whether DUSP12 contributes to ribosome
biogenesis in mammalian cells and if so, to what extent, awaits
further investigation.
In summary, we describe for the first time the establishment of a
cell line that over-expresses the dusp12 gene in isolation and
demonstrate that these cell lines are endowed with several cancer
relevant properties: increased motility, resistance to apoptosis, and
up-regulation of two genes (c-met and itga1) which are implicated in
transformation and/or metastasis. As dusp12 is present within the
1q21–1q23 amplicon present in primary liposarcomas and other
tumor types, this study suggests a possible role for DUSP12 in
cancer progression.
Materials and Methods
Plasmids and plasmid construction
The human dusp12 cDNA in plasmid pOTB7 was obtained
from OpenBiosystems. This plasmid was used as a template for
polymerase chain reaction using Pfusion polymerase (NEB) with
the following oligonucleotides incorporating 59 BamHI and 39
EcoRI restrictions sites 59-GCCCGGATCCATGTTGGAG-
GCTCCG-39 and 59-GCGAATTGTCATATTTTTCCTGTT-
39. The resulting PCR fragment was digested with BamHI and
EcoRI and ligated into the baculoviral transfer vector pFast-
BacHTB (Invitrogen) similarly digested. The clone was then
confirmed by sequencing the entire length of the insert. The
DUSP12 fragment was digested with BamHI/EcoRI and ligated
in to pEGFP-C1 (Clontech) digested with BglII/EcoRI to create
plasmid pEGFP-DUSP12.
Immunoblotting
Cells were lysed in radioimmunoprecipitation assay buffer
(RIPA) containing 1 mM phenylmethylsulfonyl fluoride, 10 mg/ml
aprotinin, and 1 mM sodium orthovanadate (Fisher). Cleared cell
lysates were obtained by centrifugation (210006 g for 10 min at
4uC) and standardized by total protein as measured by a BCA
assay (Pierce). Equivalent amounts of cleared lysates were
fractionated by SDS/PAGE and transferred to PVDF membranes
(Millipore). The membranes were blocked in 5% fat free milk in
Tris-buffered saline containing 0.1% Tween 20 (TBST) for at least
1 hour at room temperature. All primary antibodies were diluted
in blocking buffer at 1:1000 and incubated rolling at 4uC
overnight. Primary antibodies used in this study are GFP (Cell
Signaling #2555), Cleaved PARP (Cell Signaling #9541), p44/
p42 MAPK (ERK 1/2) (Cell Signaling # 4695), ITGA1 (Abcam
#ab78479), and MET (Cell Signaling #3127). HRP- linked
secondary antibodies were from Cell Signaling (#7074 and
#7076) and used at a dilution of 1:30000 in blocking buffer and
incubated at room temperature for one hour. For signal detection
the Immobilon Chemiluminescent HRP substrate was used as
recommended by the manufacturer (Millipore),and signals were
obtained by exposing blots to X-ray film (MIDSCI).
Cell culture
HEK293 cells were obtained from ATCC (CRL-1573). All
growth media, serum and supplements were purchased from
Hyclone. HEK293 cells were grown in 16 Eagle’s Minimal
Essential Medium (EMEM) supplemented with 10% fetal bovine
serum and penicillin/streptomycin. The GFP and GFP-DUSP12
HEK293 stable lines were cultured in the complete HEK293
media with the addition of 800 mg/ml G418 (Fisher). All
experiments using HEK293 or derivative cell lines were conducted
in the absence of G418 except the soft agar assays. Cells were
grown at 37 uC, 5% CO2 in a humidified chamber.
Establishment of GFP and GFP-DUSP12 stable cell lines
pEGFP-C1 or pEGFP-DUSP12 were transfected into HEK293
cells using the TransIT-293 transfection reagent (Mirus) in a 6 well
plate following the manufacturer’s recommendations. 24 hours
later, cells were washed in phosphate buffered saline (PBS),
trypsinized, and placed in one 100 mm tissue culture dish, and
allowed to attach. Complete media was removed and replaced
with complete media containing 800 mg/ml G418. Every two days
the G418 containing media was replenished. After approximately
16–20 days of selection, individual clones were isolated using
cloning discs, and individually expanded followed by screening for
the recombinant GFP-DUSP12 or GFP expression by immuno-
blotting with a GFP specific antibody.
Immunofluorescence
GFP or GFP-DUSP12 cells were seeded at 40–50% confluence
in Millipore 8 chambered slides coated with 200 mlo f5 0mg/ml
fibronectin (Sigma). After over-night attachment, cells were
washed in PBS, and complete media or serum free media was
added to the cells and incubated. After 18 hours the cells were
washed in PBS, fixed in 3.7% formaldehyde in PBS for 15 minutes
at room temperature, washed with PBS, and permeabilized using
0.2% Triton X in PBS for 10 minutes at room temperature. Cells
were labeled with rhodamine-phalloidin as described by the
manufacturer (Invitrogen). Cells were washed three times in PBS
and 100 ng/ml DAPI (Roche) was added for five minutes prior to
addition of ProLong antifade reagent (Invitrogen). Images were
taken at 1006using a Zeiss confocal microscope.
Quantitative real time PCR
Total RNA was isolated from GFP and GFP-DUSP12 stable
cell lines cultured in complete media, using the RNAeasy kit
(Qiagen) including the optional on the column DNAse treatment.
The quality of total RNA for each sample was verified by the
Agilient 2100 Bioanalyzer. cDNA was produced using the RT
2
First Strand kit as described by manufacturer (SABiosciences).
Quantitative real time PCR was performed using the RT
2 SYBR
Green Master Mix following the manufacturer’s protocol
(SABiosciences) using an iCylcer iQ Real Time PCR Detection
System (BioRad). Fold change was calculated using the DDCt
method. Expression levels of dusp12 were monitored using dusp12
specific primers described in [39]. qRT-PCR primers for
housekeeping genes (actb, b2m, and gapd) were obtained from
RealTimePrimers.com. To screen for cancer relevant genes that
dusp12 Displays Oncogenic Potential In Vitro
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cancer relevant PCR array from SABiosciences (PAHS-033) as
described by the manufacturer. The array contains 84 genes that
are known to be involved in tumorigenesis. Genes identified from
the arrays with at least a two-fold change were then verified by
qRT-PCR done in triplicate with primers for the c-met, itga1, vegfa,
cflar, and bcl2 genes from SABiosciences.
Proliferation assay
GFP or GFP-DUSP12 cells were counted using trypan blue
exclusion and a hemacytometer. 250 cells in 75 ml were seeded per
well of a 96 well plate. Viable cell number was monitored over




4 GFP or GFP-DUSP12 stable cells were suspended in
1 ml of 0.3% Difco Noble Agar (BD) in Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with 10% fetal bovine
serum, penicillin/streptomycin, and 800 mg/ml G418, and then
added to a six-well plate with a foundation layer of 0.5% agar in
triplicate. 24 hours later, the cells received 1 ml of complete
medium containing G418 before incubation for 21 days. Complete
media was replenished at least once a week to prevent drying.
Colonies were stained with .005% crystal violet (Fisher) dissolved
in phosphate buffer saline solution for one hour at 37 C. Five fields
of vision at 46 magnification were taken for each well and
analyzed for colony number and size by ImageJ (NIH).
Caspase activity
Viable cells were counted using trypan blue exclusion and a
hemacytometer. Approximately 2610
4 cells were added per well
to a 96 white walled clear bottom plate. The next day, either
staruospoine (STS) or thapsigargin (TG) (Acros Organics) were
added to the cells at a final concentration of 5 mM STS or 200 nM
TG, and incubated for an additional 16 hours or 48 hours
respectively. For both treatments addition of DMSO (Fisher)
serves as a vehicle control. Following incubation with STS or TG,
the Promega Caspase 3/7 Glo assay was performed as described
by the manufacturer. Luciferase activity was measured using a
Perkin-Elmer Victor 3V. For immunoblots examining cleaved
PARP, cells were seeded in a 100 mm plate and treated with a
final concentration of 5 mM STS, 200 nM TG, or DMSO and
lysates were collected in RIPA buffer at the indicated times.
Cell motility
For the scratch wound assay, GFP or GFP-DUSP12 cells were
placed on a coverslip in a six well plate. Once cells reached
confluence, a wound was created by using a micropipette tip.
Pictures of the same area of the scratch were taken at 106
magnification at the indicated times. Each assay was performed in
triplicate. For the transmigration assay, GFP or GFP-DUSP12
cells were pre-labeled with Calcein AM as described by the
manufacturer (BD). Following labeling, cells were suspended in
serum free media and placed in a HTS Fluorblok transwell in a 24
well format (BD). Complete medium was used as a chemoat-
tractactant. Cells were also placed in a well of the 24 well plate
without a transwell to be used to measure total fluorescent signal of
the cells. Fluorescence was read at 0 and 22 hours using a Perkin
Elmer Victor 3V. The signal at 0 hours of the transwell was
subtracted from the 22 hour read. Percent migration was
calculated by dividing the background subtracted 22 hour
transwell signal by the 22 hour signal from the control wells that
contained no transwell. Each assay was done in triplicate.
Statistics
P values were obtained using either a standard two tailed t-test
or a two- way ANOVA with Bonferroni Post-Test using GraphPad
Prism.
Supporting materials and methods are described in File S1.
Supporting Information
Figure S1 Transient expression of Flag tagged DUSP12
in HEK293 cells promotes cell motility and up-regula-
tion of c-MET. A. Left: A transmigration assay using 0.8 mm
HTS Fluoroblok transmigration chambers was performed with
fetal bovine serum as the chemoattractant. At 24 hours post
transfection, cells were pre-labeled with calcein AM and added to
the wells in serum free media. After 22 hours the total number of
live cells was measured and the percent of total cells that migrated
to the lower chamber are graphed. The means of three
independent experiments are graphed with the error bars
representing SEM. Right: Immunoblot of lysates from HEK293
cells transiently expressing Flag tagged DUSP12 or the empty
vector. Blot was probed with an anti-Flag antibody (Sigma
#F3165). Immunoblot shown is representative of three indepen-
dent experiments. B. Left: Immunoblot of lysates from HEK293
cells transiently expressing a Flag tagged DUSP12 or the empty
vector. Blot was probed with antibodies specific to c-MET, ERK
1/2 (loading control), and Flag. Immunoblot shown is represen-
tative of three independent experiments. Right: Densitometry
was performed using ImageJ. The fold change compared to the
empty vector control is graphed after normalization with the
loading control (ERK 1/2). Graphed are the results of three
independent experiments with the error bars representing SEM.
(TIF)
Acknowledgments
We would like to thank Dr. M. Teresa Ortega and the COBRE (RR17686)
for conducting the RNA quality analysis.
Author Contributions
Conceived and designed the experiments: AEB ELC. Performed the
experiments: ELC SEB. Analyzed the data: AEB ELC. Wrote the paper:
ELC AEB.
References
1. Kresse SH, Berner JM, Meza-Zepeda LA, Gregory SG, Kuo WL, et al. (2005)
Mapping and characterization of the amplicon near APOA2 in 1q23 in human
sarcomas by FISH and array CGH. Mol Cancer 4: 39.
2. Ma Y, Hendershot LM (2004) The role of the unfolded protein response in
tumour develepoment: Friend or foe? Nat Rev Cancer 4: 966–977.
3. Gratias S, Schuler A, Hitpass LK, Stephan H, Rieder H, et al. (2005) Genomic
gains on chromosome 1q in retinoblastoma: Consequences on gene expression
and association with clinical manifestation. Int J Cancer 116: 555–563.
4. Mendrzyk F, Korshunov A, Benner A, Toedt G, Pfister S, et al. (2006)
Identification of gains on 1q and epidermal growth factor receptor
overexpression as independent prognostic markers in intracranial ependymo-
ma. Clin Cancer Res 12: 2070–2079.
5. Hirai M, Yoshida S, Kashiwagi H, Kawamura T, Ishikawa T, et al. (1999) 1q23
gain is associated with progressive neuroblastoma resistant to aggressive
treatment. Genes Chromosomes Cancer 25: 261–269.
6. Guan K, Broyles SS, Dixon JE (1991) A Tyr/Ser protein phosphatase encoded
by vaccinia virus. Nature 350: 359–362.
7. Patterson KI, Brummer T, O’Brien PM, Daly RJ (2009) Dual-specificity
phosphatases: Critical regulators with diverse cellular targets. Biochem J 418:
475–489.
dusp12 Displays Oncogenic Potential In Vitro
PLoS ONE | www.plosone.org 8 April 2011 | Volume 6 | Issue 4 | e186778. Pulido R, Hooft van Huijsduijnen R (2008) Protein tyrosine phosphatases: Dual-
specificity phosphatases in health and disease. FEBS 275: 848–866.
9. Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, et al. (1999)
Increased insulin sensitivity and obesity resistance in mice lacking the protein
tyrosine phosphatase-1B gene. Science 283: 1544–1548.
10. MacKeigan JP, Murphy LO, Blenis J (2005) Sensitized RNAi screen of human
kinases and phosphatases identifies new regulators of apoptosis and chemore-
sistance. Nat Cell Biol 7: 591–600.
11. Sharda PR, Bonham CA, Mucaki EJ, Butt Z, Vacratsis PO (2009) The dual-
specificity phosphatase hYVH1 interacts with Hsp70 and prevents heat-
shock-induced cell death. Biochem J 418: 391.
12. Guan K, Hakes DJ, Wang Y, Park HD, Cooper TG, et al. (1992) A yeast protein
phosphatase related to the vaccinia virus VH1 phosphatase is induced by
nitrogen starvation. Proc Natl Acad Sci USA 89: 12175–12179.
13. Beeser AE, Cooper TG (2000) The dual-specificity protein phosphatase Yvh1p
regulates sporulation, growth, and glycogen accumulation independently of
catalytic activity in saccharomyces cerevisiae via the cycle AMP-dependent protein
kinase cascade. J of Bacto 182: 3517–3528.
14. Muda M, Manning ER, Orth K, Dixon JE (1999) Identification of the human
YVH1 protein-tyrosine phosphatase orthologue reveals a novel zinc binding
domain essential for in vivo function. J of Biol Chem 274: 23991–23995.
15. Kemmler S, Occhipiniti L, Veisu M, Panse VG (2009) Yvh1 is required for a
late maturation step in the 60S biogenesis pathway. JCB 186: 863–880.
16. Lo K, Li Z, Wang F, Marcotte EM, Johnson AW (2009) Ribosome stalk
assembly requires the dual-specificity phosphatase Yvh1 for the exchange of
Mrt4 with P0. JCB 186: 849–862.
17. Shen C, Gu M, Song C, Miao L, Hu L, et al. (2008) The tumorigenicity
diversification in human embryonic kidney 293 cell line cultured in vitro.
Biologicals 36: 263–268.
18. Croce CM (2008) Oncogenes and cancer. N Engl J Med 358: 502–511.
19. Koh DW, Dawson TM, Dawson VL (2005) Mediation of cell death by
poly(ADP-ribose) polymerase-1. Pharmacol Res 52: 5–14.
20. He Q, Montalbano J, Corcoran C, Jin W, Huang Y, et al. (2003) Effect of bax
deficiency on death receptor 5 and mitochondrial pathways during endoplasmic
reticulum calcium pool depletion-induced apoptosis. Oncogene 22: 2674–2679.
21. Lochter A, Navre M, Werb Z, Bissell MJ (1999) a1 and a2 integrins mediate
invasive activity of mouse mammary carcinoma cells through regulation of
stromelysin-1 expression. Mol Biol Cell 10: 271–282.
22. Pozzi A, Moberg PE, Miles LA, Wagne S, Soloway P, et al. (2000) Elevated
matrix metalloprotease and angiostatin levels in integrin a1 knockout mice cause
reduced tumor vascularization. PNAS 97: 2202–2207.
23. Pozzi A, Wary KK, Giancotti FG, Gardner HA (1998) Integrin a1b1 mediates a
unique collagen-dependent proliferation pathway in vivo. JCB 142: 587–594.
24. Schadendorf D, Fichtner I, Makkil A, Alijagic S, Kiipper M, et al. (1996)
Metastatic potential of human melanoma cells in nude mice characterisation of
phenotype, cytokine secretion and tumour-associated antigens. Br J Cancer 74:
194–199.
25. Senger DR, Perruzzi CA, Streit M, Koteliansky VE, de Fougerolles AR, et al.
(2002) The alpha1beta1 and alpha2beta1 integrins provide critical support for
vascular endothelial growth factor signaling, endothelial cell migration, and
tumor angiogenesis. Am J Pathol 160: 195–204.
26. Zhang YW, Vande Woude GF (2003) HGF/SF–met signaling in the control of
branching morphogenesis and invasion. J Cell Biochem 88: 408–417.
27. Martin TA, Jiang WG (2010) Hepatocyte growth factor and its receptor
signalling complex as targets in cancer therapy. Anticancer Agents Med Chem
10: 2–6.
28. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met,
metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915–925.
29. Fukuda T, Ichimura E, Shinozaki T, Sano T, Kashiwabara K, et al. (1998)
Coexpression of HGF and c-MET/HGF receptor in human bone and sof tissue
tumors. Pathol Int 48: 757–762.
30. Kuhnen C, Tolnay E, Steinau HU, Voss B, Muller KM (1998) Expression of
c-met receptor and hepatocyte growth factor/scatter factor in synovial sarcoma
and epithelioid sarcoma. Virchows Arch 432: 337–342.
31. Christensen JG, Burrows J, Salgia R (2005) c-met as a target for human cancer
and characterization of inhibitors for therapeutic intervention. Cancer Lett 225:
1–26.
32. Di Renzo MF, Olivero M, Giacomini A, Porte H, Chastre E, et al. (1995)
Overexpression and amplification of the met/HGF receptor gene during the
progression of colorectal cancer. Clin Cancer Res 1: 147–154.
33. Rahimi N, Hung W, Tremblay E, Saulnier R, Elliott B (1998) c-src kinase
activity is required for hepatocyte growth factor-induced motility and
anchorage-independent growth of mammary carcinoma cells. JBC 273:
33714–33721.
34. Tomida M, Saito T (2004) The human hepatocyte growth factor (HGF) gene is
transcriptionally activated by leukemia inhibitory factor through the stat binding
element. Oncogene 23: 679–686.
35. DeoCampo ND, Wilson MR, Trosko JE (2000) Cooperation of bcl-2 and myc in
the neoplastic transformation of normal rat liver epithelial cells is related to the
down-regulation of gap junction-mediated intercellular communication. Carci-
nogenesis 21: 1501–1506.
36. Amstad PA, Liu H, Ichimiya M, Chang S, Berezesky IK, et al. (1997) 1997.
bcl-2 enhancement of malignant transformation in mouse epidermal JB6 cells.
20:231–239. Mol Carcinog 20: 231–239.
37. Dai M, Sears R, Lu J (2007) Feedback regulation of c-myc by ribosomal protein
L11. Cell Cycle 6: 2735–2741.
38. Grandori C, Gomez-Roman N, Felton-Edkins ZA, Ngouenet C, Galloway DA,
et al. (2005) c-myc binds to human ribosomal DNA and stimulates transcription
of rRNA genes by RNA polymerase I. Nat Cell Biol 7: 310–317.
39. Caunt CJ, Armstrong SP, Rivers CA, Norman MR, McArdle CA (2008)
Spatiotemporal regulation of ERK2 by dual specificity phosphatases. JBC 283:
26612.
dusp12 Displays Oncogenic Potential In Vitro
PLoS ONE | www.plosone.org 9 April 2011 | Volume 6 | Issue 4 | e18677